Eficacia y seguridad de eltrombopag como agente trombopoyético para el tratamiento de la púrpura trombocitopénica inmune en pacientes que iniciaron tratamiento en el Complejo Asistencial Universitario de León en el periodo 2012-2015

Abstract

Immune thrombocytopenic purpura (ITP) is an autoinmune chronic disease that can lead to platelet count under 100.000/?L. Patients may develop purpuric lesions with possible hemorrhagic events. The diagnosis is made by exclusion and the treatment target is to obtain a platelet count superior to 100.000/?L.                                                                                                                                       Eltrombopag is an oral thrombopoietin receptor agonist, indicated for the second-line pharmacological treatment in splenectomized patients with chronic ITP and refractoriness to other treatments.                                                                                   The objetive of this study is to determine the efficacy and safety of the treatment. For this purpose, the dispensation registry and clinical histories of the treated patients during the period of 2012-2015 from Complejo Asistencial Universitario de León were revised.                                                                             Once the data was compiled and meticulously analysed, it can be concluded that: Most of the studied patients were able to reach the therapeutic target even though the platelet evolution didn't follow a linear progression, and the principal cause of suspension of the treatment was due to weak side effects